Our business is your health

At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.

Listen to Murray A. Goldberg, Former SVP Administration Discussing Regeneron's commitment to developing important new medicines.

Our first approved product, ARCALYST® (rilonacept), an anti-inflammatory agent, has been available to patients in the U.S. since 2008. In late 2011, we launched EYLEA® (aflibercept) Injection, also known in the scientific literature as VEGF Trap-Eye and Intravitreal Aflibercept Injection. We have subsequently received approval from the FDA for three additional indications. In 2015, PRALUENT® (alirocumab) Injection became the first approved PCSK9 inhibitor in the U.S.

We are a leader in human antibody technologies and have built a pipeline of antibody drug candidates against both novel and validated drug targets in diseases ranging from cancer to rheumatoid arthritis.

Our strategic antibody and immuno-oncology collaborations with Sanofi provide committed long-term funding and expertise to supplement our own. Our business is creating and commercializing new medicines for patients – at Regeneron our business is your health.

Form content here please :)